Adaptive Biotechnologies Corporation
ADPT
Rang in aandelen
#4168
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Aandeelprijs
$24.09
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$3.84B
Verandering (1 dag)
-5.82%
Verandering (1 jaar)
47.79%
Land
US
Handel Adaptive Biotechnologies Corporation (ADPT)
Categorie
Healthcare
Operationele marge voor Adaptive Biotechnologies Corporation (ADPT)
Operationele marge op October 2026 TTM: -12.16%
Volgens de meest recente financiële rapporten en aandelenkoers van Adaptive Biotechnologies Corporation is de huidige operationele marge (TTM) -12.16%. Eind 2024 had het bedrijf een operationele marge van -90.83%.
Geschiedenis van de operationele marge van Adaptive Biotechnologies Corporation van 2017 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | -12.16% | -41.03% |
| 2025 | -20.62% | -77.30% |
| 2024 | -90.83% | -31.88% |
| 2023 | -133.33% | 23.42% |
| 2022 | -108.03% | -20.21% |
| 2021 | -135.39% | -12.84% |
| 2020 | -155.33% | 68.56% |
| 2019 | -92.15% | 3.09% |
| 2018 | -89.39% | -22.73% |
| 2017 | -115.68% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -103.17% |
US
|
|
| -149.01% | -87.75% |
US
|
|
| 25.57% | -102.10% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -102.37% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.